metricas
covid
Buscar en
Revista Colombiana de Reumatología
Toda la web
Inicio Revista Colombiana de Reumatología Insuficiencia de vitamina D en pacientes adultos con baja masa ósea y osteoporo...
Journal Information
Vol. 17. Issue 4.
Pages 212-218 (December 2010)
Share
Share
Download PDF
More article options
Vol. 17. Issue 4.
Pages 212-218 (December 2010)
Full text access
Insuficiencia de vitamina D en pacientes adultos con baja masa ósea y osteoporosis en la Fundación Santa Fe de Bogotá 2008–2009
Vitamin D insufficiency in adults patients with low bone mass and osteoporosis in the Fundación Santa Fe de Bogotá 2008-2009
Visits
3364
Deyanira González Devia1,
Corresponding author
, Claudia Zúñiga Libreros2, William Kattah Calderón3
1 Internista Endocrinóloga, Médica institucional del Hospital Universitario Fundación Santa Fe de Bogotá. Coordinadora del grupo hueso saludable de la FSFB. Profesora de Cátedra, Facultad de Medicina, Universidad de los Andes
2 Internista, Universidad del Rosario
3 Internista Endocrinólogo, Jefe de la sección de endocrinología, Departamento de Medicina Interna, Hospital Universitario Fundación Santa Fe de Bogotá, Profesor Clínico, Facultad de Medicina, Universidad de los Andes
This item has received
Article information
Resumen

La hipovitaminosis D se asocia con osteoporosis, enfermedades neuromusculares, autoinmunes y cáncer. La prevalencia oscila entre 11% y 70% en diferentes poblaciones estudiadas. Debido a que la osteoporosis es una enfermedad frecuente, determinamos la prevalencia de hipovitaminosis D asociada a desmineralización ósea en población atendida en la FSFB entre agosto de 2008 y julio de 2009; revisamos edad, género, T-Score, Z-score. Se consideró como rango normal de 25OHD entre 32 y 150ng/dl. Hallamos 460 determinaciones de 25OHD, 105 sujetos con osteodensitometría DXA, 80% mujeres. Edad promedio 66 años (DE±12,5; rango 39 a 91); para mujeres fue 67,1 años (DE±12,2; rango 39 a 91), para hombres fue 61 años (DE±10,7; rango 42 a 82). Los niveles de 25OHD promedio fueron de 31ng/ml (DE±17,6; rango 8,2 a 110); para mujeres 30,5ng/ml (DE±16,1; rango 10,6 a 96ng/ml), para hombres 33,5ng/ml (DE±23,4; rango 8,2 a 110ng/ml). El 69,5% de casos presentaron algún nivel de insuficiencia de vitamina D, 45,7% insuficiencia leve y 23,8% insuficiencia moderada; no hay casos con insuficiencia severa. No hubo diferencias significativas entre concentraciones de 25OHD entre hombres y mujeres; o edad. La osteoporosis se correlaciona con niveles de 25OHD inferiores a 28 ng/ml (P= 0,046), pero no hay correlación entre niveles bajos de 25OHD y osteopenia. La hipovitaminosis D es muy prevalente en pacientes con osteoporosis y baja masa ósea y debe evaluarse en el contexto de osteoporosis.

Palabras clave:
vitamina D
osteoporosis
baja masa ósea
osteopenia
Summary

Hypovitaminosis D is associated with osteoporosis, neuromuscular diseases, autoimmune diseases and cancer. The prevalence varies from 11–70% in different populations. Due osteoporosis is a common disease, we determined the prevalence of hypovitaminosis D associated with bone demineralization in FSFB population evaluated between August 2008 and July 2009, we reviewed age, gender, T-Score, Z-score. Values between 32–150ng/ml were considered as normal. We found 460 25OHD results, 105 subjects with mineral density for DXA method, 80% female. Mean age for women was 66 years (SD±12.5, range 39–91) for women was 67.1 years (SD±12.2, range 39–91) for men was 61 years (SD±10.7, range 42–82). Mean 25OHD levels were 31ng / ml (SD±17.6, range 8.2 to 110), for women 30.5ng / mL (SD±16.1, range 10.6 to 96ng / mL), for men 33.5ng / mL (SD±23.4, range 8.2 to 110ng / mL). 69,5% of cases were considered as vitamin D insufficiency, 45,7% mild, 23,8% moderate, and no cases of severe déficit. No significant difference between 25OHD concentrations and gender, or age were considered. Osteoporosis was correlated with 25OHD levels below 28ng/ml (P=0,046) but not between low 25OHD and subjects with osteopenia. The vitamin D deficiency is highly prevalent in patients with osteoporosis and low bone mass and should be evaluated in the context of osteoporosis.

Key words:
vitamina D
osteoporosis
osteopenia
low bone density
Full text is only aviable in PDF
Referencias
[1.]
M.E. Elliott, N.C. Binkley, M. Carnes, et al.
Fracture risks for women in long-term care: high prevalence of calcaneal osteoporosis and hypovitaminosis D.
Pharmacotherapy, 23 (2003), pp. 702-710
[2.]
R.D. Semba, E. Garrett, B.A. Johnson, J.M. Guralnik, L.P. Fried.
Vitamin D deficiency among older women with and without disability.
Am J Clin Nutr, 72 (2000), pp. 1529-1534
[3.]
M.J. Bolland, A.B. Grey, R.W. Ames, et al.
The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency.
Am J Clin Nutr, 86 (2007), pp. 959-964
[4.]
M.F. Holick.
Vitamin D deficiency.
N Engl J Med, 357 (2007), pp. 266-281
[5.]
N.O. Kuchuk, N.M. van Schoor, S.M. Pluijm, A. Chines, P. Lips.
Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: global perspective.
J Bone Miner Res, 24 (2009), pp. 693-701
[6.]
G.R. Hart, J.L. Furniss, D. Laurie, S.K. Durham.
Measurement of vitamin D status: background, clinical use, and methodologies.
Clin Lab, 52 (2006), pp. 335-343
[7.]
P. Glendenning, M. Taranto, J.M. Noble, et al.
Current assays overestimate 25-hydroxyvitamin D3 and underestimate 25-hydroxyvitamin D2 compared with HPLC: need for assay-specific decision limits and metabolite-specific assays.
Ann Clin Biochem, 43 (2006), pp. 23-30
[8.]
R. Vieth.
Problems with direct 25-hydroxyvitamin D assays, and the target amount of vitamin D nutrition desirable for patients with osteoporosis.
Osteoporos Int, 11 (2000), pp. 635-636
[9.]
The DEQAS. Vitamin D external quality assessment scheme. Available from www.deqas.org. Accessed March 29, 2009.
[10.]
A.K. Saenger, T.J. Laha, D.E. Bremner, S.M. Sadrzadeh.
Quantification of serum 25-hydroxyvitamin D2 and D3 using HPLC-tandem mass spectrometry and examination of reference intervals for diagnosis of vitamin D deficiency.
Am J Clin Pathol, 125 (2006), pp. 914-920
[11.]
B.W. Hollis.
Comparison of Commercially Available 125I-based RIA Methods for the Determination of Circulating 25-Hydroxyvitamin D.
Clin Chem, 46 (2000), pp. 1657-1661
[12.]
G. Lensmeyer, D. Wiebe, N. Binkley, M. Drezner.
HPLC method for 25- hydroxyvitamin D measurement: comparison with contemporary assays.
Clin Chem, 52 (2006), pp. 1120-1126
[13.]
Z. Maunsell, D.J. Wright, S.J. Rainbow.
Routine isotopedilution liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of the 25-hydroxy metabolites of vitamins D2 and D3.
Clin Chem, 51 (2005), pp. 1683-1690
[14.]
R.L. Horst, B.W. Hollis.
Vitamin D assays and their clinical utility.
Physiology, Molecular Biology, and Clinical Applications, pp. 239-271
[15.]
J.C. Souberbielle, V. Fayol, C. Sault, E. Lawson-Body, A. Kahan, C. Cormier.
Assay-specific decision limits for two new automated parathyroid hormone and 25-hydroxyvitamin D assays.
Clin Chem, 51 (2005), pp. 395-400
[16.]
K.W. Phinney.
Development of a standard reference material for vitamin D in Serum.
Am J Clin Nutr, 88 (2008), pp. 511S-512S
[17.]
G.D. Carter, R. Carter, J. Jones, J. Berry.
How accurate are assays for 25-hydroxyvitamin D? Data from the international vitamin D external quality assessment scheme.
Clin Chem, 50 (2004), pp. 2195-2197
[18.]
A.C. Looker, B. Dawson-Hughes, M.S. Calvo, et al.
Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III.
Bone, 30 (2002), pp. 771-777
[19.]
G.L. Saraiva, M.S. Cendoroglo, L.R. Ramos, L.M. Araújo, J.G. Vieira, S.S. Maeda, V.Z. Borba, I. Kunii, L.F. Hayashi, M. Lazaretti-Castro.
Prevalence of vitamin D deficiency, insufficiency and secondary hyperparathyroidism in the elderly inpatients and living in the community of the city of São Paulo.
Brazil Arq Bras Endocrinol Metabol, 51 (2007), pp. 437-442
[20.]
M.F. Holick.
Vitamin D requirements for humans of all ages: new increased requirements for women and men 50 years and older.
Osteoporos Int, 8 (1998), pp. S24-S29
[21.]
National Institute of Standards and Technology (NIST) Chemical Science and Technology Laboratory. NIST releases vitamin D standard reference material. Available from http://www.nist.gov/cstl/analytical/vitamind_071409.cfm. Accessed August 7, 2009.
[22.]
J.E. Isenor, M.H.H. Ensom.
Is There a Role for Therapeutic Drug Monitoring of Vitamin D Level as a Surrogate Marker for Fracture Risk?.
Pharmacotherapy, 30 (2010), pp. 254-264
Copyright © 2010. Asociación Colombiana de Reumatología
Download PDF
Article options